REducing Sympathetic Activity Through Ultrasound-based Renal deneRvation in Excessive Cardiovascular Risk populaTions - the RESURRECT Trial. A Pilot Proof-of-concept and Safety Study With the Paradise Denervation System
Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
The is a non-randomized pilot trial, open-label evaluation of the physiologic response of native kidney denervation using the Paradise denervation system in CKD, End Stage Renal Disease (ESRD), and Heart failure (HF)
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• Both Male and female patients
• Ages between 18-75 years of age
• Individual is competent and willing to provide written, informed consent to participate in this clinical study with either
‣ CKD stage 3a/b or
⁃ ESRD on stable renal replacement therapy or
⁃ Mild to moderate heart failure with reduced ejection fraction
Locations
Other Locations
Australia
Royal Perth Hospital
RECRUITING
Perth
Contact Information
Primary
Anu Joyson
anu.joyson@uwa.edu.au
92240390
Backup
Markus Schlaich
markus.schlaich@uwa.edu.au
92240382
Time Frame
Start Date: 2021-10-08
Estimated Completion Date: 2026-05-18
Participants
Target number of participants: 75
Treatments
Experimental: Chronic Kidney Disease
Renal Denervation
Experimental: Heart Failure
Renal Denervation
Experimental: End stage renal disease
Renal Denervation
Related Therapeutic Areas
Sponsors
Leads: Royal Perth Hospital
Collaborators: ReCor Medical, Inc.